Clinical Trial Update: Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating nivolumab plus temozolomide in patients with recurrent or refractory small-cell lung cancer or advanced neuroendocrine …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• Temodar (Temozolomide)
• nivolumab (nivolumab)

Snippet

Sponsor: Dwight Owen | Conditions: Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING